Investor Updates: Eli Lilly and Co (NYSE:LLY), St. Jude Medical, Inc. (NYSE:STJ), EXACT Sciences Corporation (NASDAQ:EXAS)

Eli Lilly and Co (NYSE:LLY), the drug maker entered into an agreement to sell major U.S. veterinary products, currently marketed by Novartis (NVS) Animal Health, to independent pharmaceutical company Virbac. Eli Lilly agreed to divest these assets in connection with the U.S. Federal Trade Commission's review of the company's pending acquisition of Novartis Animal Health worldwide. The transaction is subject to approval by the U.S. Federal Trade Commission, and is also dependent on the closing of Eli Lilly's acquisition of Novartis Animal Health. Eli Lilly and Co (NYSE:LLY) shares are moving near the top end of the 52-week range of $48.88 - $67.14.St. Jude Medical, Inc. (NYSE:STJ), a medical device supplier, has received approval from the U.S. Food and Drug Administration (FDA) for its TactiCath Quartz irrigated ablation catheter, a contact-force measurement for treating patients with atrial fibrillation. The product was designed to give physicians a real-time, objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure."The number of patients with atrial fibrillation is growing rapidly in the U.S.," said Dr. Vivek Reddy, director of electrophysiology at Mount Sinai Hospital, N.Y. "As the number of patients impacted by this disease continues to grow, it is important to develop treatment solutions that increase the efficiency and effectiveness of ablation therapies. TactiCath Quartz is an important advancement that provides critical information during ablation procedures." Shares of St. Jude Medical, Inc. (NYSE:STJ) are at $60.47 within a 52-week range of $54.80 - $71.90.EXACT Sciences Corporation (NASDAQ:EXAS) reported a larger-than-expected Q3 loss, as the molecular-diagnostics company said its Cologuard stool-based DNA test has received "significant demand" from physicians and patients. EXAS is trading near the high end of its 52-week range of $10.46 to $26.79. EXACT Sciences Corporation (NASDAQ:EXAS) posted a Q3 net loss of $32.1 million, or $0.39 per share, compared with a loss of $11.2 million, or $0.16 per share, a year earlier. There were 18% more diluted shares in the latest period, skewing the per-share comparison. Analysts polled by Capital IQ were expecting a loss of $0.31 per share.The company recorded no revenue in the latest quarter, versus the receipt of $1 million in license fees in the prior-year period. Analysts had predicted about $130,000 in revenue for the latest quarter. Its wider loss in the latest quarter came as operating expenses nearly tripled to $32.2 million from $11.2 million a year earlier. The company said following Medicare officially making its Cologuard stool-based DNA test available to its beneficiaries on Oct. 9 and issuing a preliminary pricing decision, "we are very pleased with the significant demand from physicians and patients, and the early uptake of Cologuard since Medicare's final national coverage decision." Cologuard is the first and only FDA-approved stool-based DNA test.